SEHESTED MAXWELL,JENSEN PETER BUHL,NISSEN NIS,SEHESTED Maxwell,JENSEN Peter Buhl,NISSEN Nis
申请号：
SI200931197
公开号：
SI2262493T1
申请日:
2009.03.06
申请国别(地区):
SI
年份:
2015
代理人:
摘要：
The present invention relates generally to the treatment of diseases and disorders that are mediated by histone deacetylase (HDAC), for example, cancer, with Belinostat&trade； (also known as (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide； PXD101； and PX 105684), and more particularly, to improvement treatments of such diseases (for example, cancers, for example, leukemias), which employ prolonged continuous infusion (e.g., prolonged continuous intravenous infusion) of Belinostat&trade；.
